Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease

Brain

Volumn 123, Issue 7, 2000, Pages 1380-1390

  Brundin, Patrik ^b   Pogarell, Oliver ^e,f   Hagell, Peter ^a   Piccini, Paola ^d   Widner, Håkan ^a,b   Schrag, Anette ^c   Kupsch, Andreas ^e   Crabb, Lesley ^c   Odin, Per ^a   Gustavii, Björn ^a   Björklund, Anders ^b   Brooks, David J ^d   Marsden, C David ^c   Oertel, Wolfgang H ^e,f   Quinn, Niall P ^c   Rehncrona, Stig ^a   Lindvall, Olle ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Dopamine; Lazaroid; Neural transplantation; Parkinson's disease; Positron emission tomography

Indexed keywords

FLUORINE 18; LAZAROID; LEVODOPA; TIRILAZAD;

ADULT; AGED; ARTICLE; BRAIN GRAFT; CAUDATE NUCLEUS; CLINICAL ARTICLE; EMBRYONAL TISSUE; GRAFT SURVIVAL; HUMAN; MESENCEPHALON; MOTOR ACTIVITY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RATING SCALE;

EID: 0033934144     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/123.7.1380     Document Type: Article

References (51)

1. Barker RA, Dunnett SB, Faissner A, Fawcett JW. The time course of loss of dopaminergic neurons and the gliotic reaction surrounding grafts of embryonic mesencephalon to the striatum. [Review]. Exp Neurol 1996; 141: 79-93.
2. Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 1994; 117: 859-76.
3. Björklund A, Dunnett SB, Nikkhah G. Nigral transplants in the rat Parkinson model. Functional limitations and strategies to enhance nigrostriatal reconstruction. In: Dunnett SB, Björklund A, editors. Functional neural transplantation. New York: Raven Press; 1994. p. 47-69.
4. Björklund L, Spenger C, Strömberg I. Tirilazad mesylate increases dopaminergic neuronal survival in the oculo grafting model. Exp Neurol 1997; 148: 324-33.
5. Braughler JM, Hall ED, Jacobsen EJ, McCall JM, Means ED. The 21-aminosteroids: potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia. Drugs Future 1989; 14: 143-52.
6. Brundin P, Karlsson J, Emgård M, Kaminski Schierle GS, Hansson O, Petersén Å, et al. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant 2000; 9: 179-95.
7. Defer GL, Geny C, Ricolfi F, Fenelon G, Monfort JC, Remy P, et al. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain 1996; 119: 41-50.
8. Doucet G, Brundin P, Descarries L, Björklund A. Effect of prior dopamine denervation on survival and fiber outgrowth from intrastriatal fetal mesencephalic grafts. Eur J Neurosci 1990; 2: 279-90.
9. Duan WM, Widner H, Brundin P. Temporal pattern of host responses against intrastriatal grafts of syngeneic, allogeneic or xenogeneic embryonic neuronal tissue in rats. Exp Brain Res 1995; 104: 227-42.
10. Emgård M, Karlsson J, Hansson O, Brundin P. Patterns of cell death and dopaminergic neuron survival in intrastriatal nigral grafts. Exp Neurol 1999; 160: 279-88.
11. Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995; 38: 379-88.
12. Frodl EM, Nakao N, Brundin P. Lazaroids improve the survival of cultured rat embryonic mesencephalic neurones. Neuroreport 1994; 5: 2393-6.
13. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-52.
14. Grasbon-Frodl EM, Nakao N, Brundin P. The lazaroid U-83836E improves the survival of rat embryonic mesencephalic tissue stored at 4 degrees C and subsequently used for cultures or intracerebral transplantation. Brain Res Bull 1996; 39: 341-47.
15. Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, et al. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain 1999; 122: 1121-32.
16. Hagell P, Crabb L, Pogarell O, Schrag A, Widner H, Brooks DJ, et al. Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. Mov Disord 2000; 15: 224-9.
17. Hansson O, Castilho RF, Kaminski Schierle GS, Karlsson J, Nicotera P, Leist M, et al. Additive effects of caspase inhibitor and lazaroid on the survival of transplanted rat and human embryonic dopamine neurons. Exp Neurol. In press 2000.
18. Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999; 56: 179-87.
19. Holthoff-Detto VA, Kessler J, Herholz K, Bonner H, Pietrzyk U, Wurker M, et al. Functional effects of striatal dysfunction in Parkinson disease. Arch Neurol 1997; 54: 145-50.
20. Karlsson J, Love RM, Clarke DJ, Brundin P. Effects of anaesthetics and lazaroid U-83836E on survival of transplanted rat dopaminergic neurones. Brain Res 1999; 821: 546-50.
21. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJ, Mufson EJ, Sanberg PR, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332: 1118-24.
22. Kordower JH, Rosenstein JM, Collier TJ, Burke MA, Chen EY, Li JM, et al. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 1996; 370: 203-30.
23. Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sanberg PR, Hauser RA, et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 1998; 13: 383-93.
24. Langston JW, Widner H. Goetz CG, Brooks D, Fahn S, Freeman T, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7: 2-13.
25. Lindvall O. Cerebral implantation in movement disorders: state of the art. Mov Disord 1999; 14: 201-5.
26. Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 1989; 46: 615-31.
27. Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990; 247: 574-7.
28. Lindvall O, Widner H, Rehncrona S, Brundin P, Odin P, Gustavii B, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 1992; 31: 155-65.
29. Lindvall O, Sawle G, Widner H, Rothwell JC, Björklund A, Brooks D, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35: 172-80.
30. Mayer E, Fawcett JW, Dunnett SB. Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons - II. Effects on nigral transplants in vivo. Neuroscience 1993; 56: 389-98.
31. Nakao N, Frodl EM, Duan WM, Widner H, Brundin P. Lazaroids improve the survival of grafted rat embryonic dopamine neurons. Proc Natl Acad Sci USA 1994; 91: 12408-12.
32. Othberg A, Keep M, Brundin P, Lindvall O. Tirilazad mesylate improves survival of rat and human embryonic mesencephalic neurons in vitro. Exp Neurol 1997; 147: 498-502.
33. Peschanski M, Defer G, N'Guyen JP, Ricolfi F, Monfort JC, Remy P, et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994; 117: 487-99.
34. Piccini P, Brooks DJ, Björklund A, Gunn RN, Grasby PM, Rimoldi O, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999; 2: 1137-40.
35. Rehncrona S. A critical review of the current status and possible developments in brain transplantation. Adv Tech Stand Neurosurg 1997; 23: 3-46.
36. 18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 1995; 38: 580-8.
37. Rosenblad C, Martinez-Serrano A, Bjorklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 1996; 75: 979-85.
38. Sauer H, Brundin P. Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts. Rest Neurol Neurosci 1991; 2: 123-35.
39. Sautter J, Tseng JL, Braguglia D, Aebischer P, Spenger C, Seiler RW, et al. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp Neurol 1998; 149: 230-6.
40. 18F]6-L-fluorodopa studies in two patients with putaminal implants. Ann Neurol 1992; 31: 166-73.
41. Schierle GS, Hansson O, Leist M, Nicotera P, Widner H, Brundin P. Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat Med 1999; 5: 97-100.
42. Sinclair SR, Svendsen CN, Torres EM, Martin D, Fawcett JW, Dunnett SB. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. Neuroreport 1996; 7: 2547-52.
43. Studer L, Tabar V, McKay RD. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat Neurosci 1998; 1: 290-5.
44. Sullivan AM, Pohl J, Blunt SB. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. Eur J Neurosci 1998; 10: 3681-8.
45. Takayama H, Ray J, Raymon HK, Baird A, Hogg J, Fisher LJ, et al. Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease. Nat Med 1995; 1: 53-8.
46. Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 1997; 42: 95-107.
47. Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B, et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 1992; 327: 1556-63.
48. Wilby MJ, Sinclair SR, Muir EM, Zietlow R, Adcock KH, Horellou P, et al. A glial cell line-derived neurotrophic factor-secreting clone of the Schwann cell line SCTM41 enhances survival and fiber outgrowth from embryonic nigral neurons grafted to the striatum and to the lesioned substantia nigra. J Neurosci 1999; 19: 2301-12.
49. Yurek DM. Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Exp Neurol 1998; 153: 195-202.
50. Zawada WM, Zastrow DJ, Clarkson ED, Adams FS, Bell KP, Freed CR. Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats. Brain Res 1998; 786: 96-103.
51. Zeng BY, Jenner P, Marsden CD. Altered motor function and graft survival produced by basic fibroblast growth factor in rats with 6-OHDA lesions and fetal ventral mesencephalic grafts are associated with glial proliferation. Exp Neurol 1996; 139: 214-26.